← Back to AI Offer
Mendelian Health
About
Mendelian is a leading company in the diagnosis of rare diseases. Our platform, MendelScan, scans EHRs to identify patients with undiagnosed rare diseases.
Key Facts
- Mendelian has existing partnerships with the NHS, with an expected coverage of 24 million patients by 2022.
- Mendelian has ongoing projects with some of the largest pharmaceutical companies.
- Mendelian has 30 algorithms for rare diseases deployed.
Successes in UK/NHS
- Modality Partnership. A national pilot project with the largest NHS GP practice partnership covering 45 practices and 450,000 patients.
- Mendelian is part of a Genomics Medical Services Alliance (GMSA) / NHS England Digital Transformational project covering 2 large regional footprints. North East & Yorkshire GMSA and Central & South GMSA, covering 6 PCNs and approx 300,000 patients
- Mendelian is partnering with NHS Southport & Formby CCG, piloting in up to 17 practices with 127,000 patients
- Successful pilot completed with Hertfordshire CCG, covering 9 practices and ~75,000 patients
Organisation details
Part of our AI offer
Learn more →
Website
www.mendelian.co ↗Details
Markets already exporting to
Early stages of starting pilot in Denmark and outreach in US.
Desired Markets
Nordics, EU4, US, Canada, Israel. Interested in all other markets as well.
Desired customer types
Pharma, biotech, genetic testing companies, payers, insurance
Specialism
AI Services